AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01880619
Drug: Solifenacin
RxNorm normalized name: Solifenacin
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the arm will receive Solifenacin
Trial: NCT01880619
Drug: Control
RxNorm normalized name: Control
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in this are will receive placebo
Trial: NCT01034189
Drug: Cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3\~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
Trial: NCT01034189
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
Trial: NCT01034189
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
Trial: NCT00928083
Drug: OZ439 200mg API capsules
RxNorm normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00960427
Drug: systemic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02402062
Drug: TH-302 + Sunitinib
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Combination of the two drugs in cycles of 28 days, described as follows:~Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.~TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle.
Trial: NCT01577914
Drug: Carvedilol Tablets USP 12.5 mg
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5mg tablet once a day
Trial: NCT01577914
Drug: Carvedilol
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12.5mg tablet once a day
Trial: NCT01937299
Drug: Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01937299
Drug: Travoprost 0.004% ophthalmic solution
RxNorm normalized name: Travoprost 0.004% Ophthalmic Solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01550926
Drug: 120 mg orlistat
RxNorm normalized name: orlistat 120 MG
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 X60 mg capsule
Trial: NCT01550926
Drug: 60 mg orlistat
RxNorm normalized name: orlistat 60 MG
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg orlistat
Trial: NCT01550926
Drug: orlistat experimental dose
RxNorm normalized name: Orlistat
DrugBank: Orlistat (DB01083)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: experimental
Trial: NCT00928083
Drug: OZ439 100mg API capsules
RxNorm normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 100mg (2x50mg API capsules)
Trial: NCT00928083
Drug: OZ439 400mg API capsules
RxNorm normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 400mg (2x200mg API capsules)
Trial: NCT00091858
Drug: Darbepoetin Alfa
RxNorm normalized name: Darbepoetin Alfa
DrugBank: Darbepoetin alfa (DB00012)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6.75 mcg/kg Q4W
Trial: NCT03167918
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: gave each patient 1000 mg, bid, PO
Trial: NCT03167918
Drug: Mecobalamin Tablets
RxNorm normalized name: mecobalamin Oral Tablet
DrugBank: Mecobalamin (DB03614)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: gave each patient 0.5 mg bid, PO
Trial: NCT00928083
Drug: OZ439 800mg API capsules
RxNorm normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 800mg (4x200 API capsules)
Trial: NCT00928083
Drug: OZ439 1200mg API capsules
RxNorm normalized name: API
DrugBank: Alpha-1-proteinase inhibitor (DB00058)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OZ439 1200mg (6x200mg API capsules)
Trial: NCT00153283
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00099528
Drug: REN-1654
RxNorm normalized name: Ren shen
DrugBank: Ginseng (DB01404)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00219297
Drug: Patupilone
RxNorm normalized name: Patupilone
DrugBank: Patupilone (DB03010)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00039611
Drug: oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04502069
Drug: Opaganib
RxNorm normalized name: Opaganib
DrugBank: Opaganib (DB12764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg Q12 hours orally
Trial: NCT04217720
Drug: SNS-301
RxNorm normalized name: sn-3-GPC
DrugBank: Choline alfoscerate (DB04660)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SNS-301 (1x 1011 dose/1ml) ID injection every 3 weeks for 4 doses then every 6 weeks for 6 additional doses, and thereafter every 12 weeks up to 24 months.
Trial: NCT00724568
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
Trial: NCT00724568
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
Trial: NCT00724568
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
Trial: NCT00724568
Drug: Doxil
RxNorm normalized name: Doxil
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will be treated with Doxil on day 4.
Trial: NCT00520741
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
Trial: NCT00520741
Drug: Lacosamide
RxNorm normalized name: Lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
Trial: NCT00999869
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
Trial: NCT01206166
Drug: Olimel (5.7%E / N9E)
RxNorm normalized name: vitamin E 5 UNT
DrugBank: Lime (citrus) (DB10635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
Trial: NCT00999869
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
Trial: NCT02532764
Drug: QR-010
RxNorm normalized name: mannitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
Trial: NCT01683175
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01683175
Drug: cis-platinum
RxNorm normalized name: cis-Platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01683175
Drug: Vinorelbine
RxNorm normalized name: Vinorelbine
DrugBank: Vinorelbine (DB00361)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03103100
Drug: 1% Lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mL of 1% lidocaine
Trial: NCT03103100
Drug: 0.25% Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mL of 0.25% bupivacaine
Trial: NCT03103100
Drug: Bupivacaine plus Lidocaine
RxNorm normalized name: bupivacaine / lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
Trial: NCT00531206
Drug: Tipranavir
RxNorm normalized name: Tipranavir
DrugBank: Tipranavir (DB00932)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00531206
Drug: Ritonavir
RxNorm normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: low dose
Trial: NCT03463512
Drug: Racecadotril plus ORS
DrugBank: Racecadotril (DB11696)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Racecadotril plus ORS
Trial: NCT03463512
Drug: ORS
RxNorm normalized name: HORSE
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ORS
Trial: NCT00003399
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003399
Drug: cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003399
Drug: dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003399
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003399
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00003399
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01695109
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: sc injections of 0.6 mg Liraglutide daily for three continuous days.
Trial: NCT03505853
Drug: Givosiran
RxNorm normalized name: Givosiran
DrugBank: Givosiran (DB15066)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: single dose of givosiran by subcutaneous (sc) injection
Trial: NCT03505853
Drug: 5-probe cocktail
RxNorm normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: includes midazolam, caffeine, losartan, omeprazole, and dextromethorphan
Trial: NCT02635243
Drug: r-glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:solution~Route of administration: subcutaneous
Trial: NCT02635243
Drug: insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:solution~Route of administration: intravenous
Trial: NCT04343144
Drug: Nivolumab Injection
RxNorm normalized name: nivolumab Injection
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Treatment consists of an infusion of OPDIVO® 3mg/kg on day 1 (D1).
Trial: NCT03510559
Drug: Forearm Nerve Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blockade of the arm below the elbow using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
Trial: NCT03510559
Drug: Brachial Plexus Block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Blockade of the entire arm using local anesthetic (0.5% bupivacaine and 2% lidocaine) deposited under ultrasound guidance to facilitate performance of the surgical procedure.
Trial: NCT01347788
Drug: cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib PO QD
Trial: NCT03331042
Drug: SM-1
RxNorm normalized name: SM-153
DrugBank: Samarium Sm-153 (DB12905)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-drug combination product containing 50-mg diphenhydramine, 5-mg delayed-release zolpidem and 0.5-mg delayed-release lorazepam.
Trial: NCT03331042
Drug: D+Z
RxNorm normalized name: Dextromethorphan and Quinidine
DrugBank: Dextromethorphan (DB00514)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-drug combination comparator product containing 50-mg diphenhydramine and 5-mg delayed-release zolpidem.
Trial: NCT03331042
Drug: D+L
RxNorm normalized name: D,L-nomifensine
DrugBank: Nomifensine (DB04821)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2-drug combination comparator product containing 50-mg diphenhydramine and 0.5-mg delayed-release lorazepam.
Trial: NCT01034553
Drug: Aurora A kinase inhibitor MLN8237
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given orally
Trial: NCT01034553
Drug: bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given IV
Trial: NCT04032548
Drug: Propolis mouthwash
RxNorm normalized name: propolis
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Trial: NCT04032548
Drug: Chlorhexidine mouthwash
RxNorm normalized name: chlorhexidine Mouthwash
DrugBank: Chlorhexidine (DB00878)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After using mouthwash for 21 days, they are instructed to refrain from mouthwash for 14 days (wash out period).
Trial: NCT01752257
Drug: EF5 Hypoxia
RxNorm normalized name: Hypoxis hemerocallidea root extract
DrugBank: St. John's Wort (DB01323)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EF5 is a dye used to measure hypoxia
Trial: NCT01260948
Drug: Donepezil Hydrochloride
RxNorm normalized name: Donepezil Hydrochloride
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg Orally Disintegrating Tablet
Trial: NCT01260948
Drug: Aricept®
DrugBank: Rice (DB10563)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Orally Disintegrating Tablet
Trial: NCT03765502
Drug: IM Glucagon
RxNorm normalized name: Glucagon
DrugBank: Glucagon (DB00040)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered IM via GEK
Trial: NCT02552940
Drug: Tocilizumab
RxNorm normalized name: Tocilizumab
DrugBank: Tocilizumab (DB06273)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
Trial: NCT00060866
Drug: Propranolol
RxNorm normalized name: Propranolol
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01159548
Drug: Promethazine
RxNorm normalized name: Promethazine
DrugBank: Promethazine (DB01069)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00398229
Drug: s.c. human chorionic gonadotropin (Ovitrelle)
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: S.C. Ovitrelle 250 mcg once
Trial: NCT00437762
Drug: Botulinum Toxin A Injection
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Botulinum Toxin A Injection
Trial: NCT00376948
Drug: erlotinib hydrochloride
RxNorm normalized name: Erlotinib Hydrochloride
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00376948
Drug: gemcitabine hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00846625
Drug: triamcinolone
RxNorm normalized name: Triamcinolone
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravitreal injection (4 mg/0.1 ml)
Trial: NCT00846625
Drug: ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravitreal injection, 0.5 mg
Trial: NCT00688064
Drug: Adapalene BPO Gel associated with Doxycyline Hyclate
RxNorm normalized name: adapalene Topical Gel
DrugBank: Adapalene (DB00210)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
Trial: NCT01706328
Drug: Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
Trial: NCT01706328
Drug: Salbutamol as needed
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation powder
Trial: NCT00787761
Drug: busulfan
RxNorm normalized name: Busulfan
DrugBank: Busulfan (DB01008)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Commercially available in 60 mg/10 mL ampuls.~Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.~Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.~IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses.
Trial: NCT01769586
Drug: Diphenhydramine
RxNorm normalized name: Diphenhydramine
DrugBank: Diphenhydramine (DB01075)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01769586
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT04236778
Drug: VE303
RxNorm normalized name: VE303
DrugBank: VE303 (DB17794)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The VE303 Drug Product is a live biotherapeutic product (LBP) consisting of 8 clonal human commensal bacterial strains manufactured under GMP conditions.
Trial: NCT04236778
Drug: Oral Vancomycin
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin, when taken by mouth, is used to treat Clostridium difficile-associated diarrhea.
Trial: NCT00583544
Drug: TC-2216
RxNorm normalized name: TC-2216
DrugBank: TC-2216 (DB06044)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple ascending dose groups will be explored.
Trial: NCT04468711
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D plus topical 1% hydrocortisone cream twice daily
Trial: NCT00068185
Drug: Black cohosh
RxNorm normalized name: black cohosh
DrugBank: Black cohosh (DB13975)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00787761
Drug: fludarabine phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.~Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.~Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.~Fludarabine will be administered as an IV infusion over 30 minutes.
Trial: NCT00787761
Drug: tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).~Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.~Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.~Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F).
Trial: NCT01138072
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg atorvastatin single dose
Trial: NCT03272139
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Anesthetic that will help treat pain and sensation after shoulder arthroscopy
Trial: NCT00725439
Drug: Talarozole
RxNorm normalized name: Talarozole
DrugBank: Talarozole (DB13083)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Dose 1.0 mg once daily